PT-141 10mg from Adaptog Peptides, also known as Bremelanotide, is a synthetic melanocortin receptor agonist used in research on the central melanocortin system. Investigators select PT-141 for its activity at MC3R and MC4R receptors, which makes it a valuable tool for studies on neural signalling, sexual-response pathways, and energy-balance regulation. Adaptog supplies PT-141 10mg at consistent laboratory-grade purity.
PT-141 was developed as a melanocortin agonist with selectivity that distinguishes it from earlier melanotan compounds. Its activity at central melanocortin receptors places it at the centre of research programmes investigating neural-behavioural pathways, appetite regulation, and reproductive signalling. Adaptog Peptides supplies PT-141 10mg as a high-purity reagent suited to receptor-binding and pharmacology studies.
Researchers often buy PT-141 10mg from Adaptog Peptides for tasks such as:
Investigating MC3R and MC4R receptor activation and binding kinetics
Examining central pathways involved in sexual-response research
Studying melanocortin involvement in feeding behaviour and energy balance
Comparing the pharmacological profile of PT-141 against other melanocortin agonists
Because PT-141 is a well-characterised melanocortin agonist, it supports detailed work in receptor pharmacology and behavioural neuroscience. Adaptog Peptides delivers PT-141 10mg as a research-grade compound prepared strictly for qualified laboratory environments. It is not for clinical, diagnostic, or therapeutic use.
For research use only. Not for human consumption.
PT-141 was developed as a melanocortin agonist with selectivity that distinguishes it from earlier melanotan compounds. Its activity at central melanocortin receptors places it at the centre of research programmes investigating neural-behavioural pathways, appetite regulation, and reproductive signalling. Adaptog Peptides supplies PT-141 10mg as a high-purity reagent suited to receptor-binding and pharmacology studies.
Researchers often buy PT-141 10mg from Adaptog Peptides for tasks such as:
Investigating MC3R and MC4R receptor activation and binding kinetics
Examining central pathways involved in sexual-response research
Studying melanocortin involvement in feeding behaviour and energy balance
Comparing the pharmacological profile of PT-141 against other melanocortin agonists
Because PT-141 is a well-characterised melanocortin agonist, it supports detailed work in receptor pharmacology and behavioural neuroscience. Adaptog Peptides delivers PT-141 10mg as a research-grade compound prepared strictly for qualified laboratory environments. It is not for clinical, diagnostic, or therapeutic use.
For research use only. Not for human consumption.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Not a researcher? Exit
